U.S. FDA Accepts Supplemental New Drug Application for Deucravacitinib (Sotyktu, Bristol Myers Squibb) in PsA July 21, 2025
Boehringer Ingelheim and LEO Pharma Partner to Commercialize and Further Develop IL-36 Blocker Spesolimab (Spevigo) July 14, 2025
Hawaii Tops List of States With the Most Google Searches for Skin Conditions and Treatments July 8, 2025
NPF Expands Seal of Recognition to FDA-approved Treatments; First Seal Goes to Roflumilast 0.3% (Zoryve, Arcutis) June 2, 2025
PsO Pipeline Update: Enrollment Complete in Phase 3 Program of Alumis’ Oral TYK2 Inhibitor May 29, 2025
Switching Biologics in Psoriasis: First Person Dosed in New Study of Anti-IL-17 Treatment-Resistant Patients May 29, 2025
Expert Reaction: U.S. FDA Approves Roflumilast Foam 0.3% (Zoryve, Arcutis) for Plaque Psoriasis of the Scalp and Body May 22, 2025
U.S. FDA Gives Its Nod to Roflumilast Foam 0.3% (Zoryve, Arcutis) for Plaque Psoriasis of the Scalp and Body May 22, 2025
